Literature DB >> 26629316

Global histone post-translational modifications and cancer: Biomarkers for diagnosis, prognosis and treatment?

Shafqat Ali Khan1, Divya Reddy1, Sanjay Gupta1.   

Abstract

Global alterations in epigenetic landscape are now recognized as a hallmark of cancer. Epigenetic mechanisms such as DNA methylation, histone modifications, nucleosome positioning and non-coding RNAs are proven to have strong association with cancer. In particular, covalent post-translational modifications of histone proteins are known to play an important role in chromatin remodeling and thereby in regulation of gene expression. Further, histone modifications have also been associated with different aspects of carcinogenesis and have been studied for their role in the better management of cancer patients. In this review, we will explore and discuss how histone modifications are involved in cancer diagnosis, prognosis and treatment.

Entities:  

Keywords:  Cancer; Diagnosis; Epigenetics; Histone post-translational modifications; Prognosis; Treatment

Year:  2015        PMID： 26629316      PMCID： PMC4657128          DOI： 10.4331/wjbc.v6.i4.333

Source DB:  PubMed          Journal:  World J Biol Chem        ISSN： 1949-8454


  143 in total

Review 1.  Epigenetic therapy of cancer: past, present and future.

Authors:  Christine B Yoo; Peter A Jones
Journal:  Nat Rev Drug Discov       Date:  2006-01       Impact factor: 84.694

Review 2.  When signaling kinases meet histones and histone modifiers in the nucleus.

Authors:  Sung Hee Baek
Journal:  Mol Cell       Date:  2011-05-06       Impact factor: 17.970

3.  Crystal structure of the nucleosome core particle at 2.8 A resolution.

Authors:  K Luger; A W Mäder; R K Richmond; D F Sargent; T J Richmond
Journal:  Nature       Date:  1997-09-18       Impact factor: 49.962

4.  Identification of 67 histone marks and histone lysine crotonylation as a new type of histone modification.

Authors:  Minjia Tan; Hao Luo; Sangkyu Lee; Fulai Jin; Jeong Soo Yang; Emilie Montellier; Thierry Buchou; Zhongyi Cheng; Sophie Rousseaux; Nisha Rajagopal; Zhike Lu; Zhen Ye; Qin Zhu; Joanna Wysocka; Yang Ye; Saadi Khochbin; Bing Ren; Yingming Zhao
Journal:  Cell       Date:  2011-09-16       Impact factor: 41.582

5.  Constitutive expression of γ-H2AX has prognostic relevance in triple negative breast cancer.

Authors:  Anika Nagelkerke; Simon J A van Kuijk; Fred C G J Sweep; Iris D Nagtegaal; Nicoline Hoogerbrugge; John W M Martens; Mieke A Timmermans; Hanneke W M van Laarhoven; Johan Bussink; Paul N Span
Journal:  Radiother Oncol       Date:  2011-08-15       Impact factor: 6.280

6.  A phase I study of histone deacetylase inhibitor, pracinostat (SB939), in pediatric patients with refractory solid tumors: IND203 a trial of the NCIC IND program/C17 pediatric phase I consortium.

Authors:  Alexandra P Zorzi; Mark Bernstein; Yvan Samson; Donna A Wall; Sunil Desai; Darcy Nicksy; Nancy Wainman; Elizabeth Eisenhauer; Sylvain Baruchel
Journal:  Pediatr Blood Cancer       Date:  2013-07-25       Impact factor: 3.167

7.  Phase I pharmacokinetic and pharmacodynamic study of LAQ824, a hydroxamate histone deacetylase inhibitor with a heat shock protein-90 inhibitory profile, in patients with advanced solid tumors.

Authors:  Johann S de Bono; Rebecca Kristeleit; Anthony Tolcher; Peter Fong; Simon Pacey; Vasilios Karavasilis; Monica Mita; Heather Shaw; Paul Workman; Stan Kaye; Eric K Rowinsky; Wynne Aherne; Peter Atadja; Jeffrey W Scott; Amita Patnaik
Journal:  Clin Cancer Res       Date:  2008-10-15       Impact factor: 12.531

8.  Proliferation indices of phosphohistone H3 and Ki67: strong prognostic markers in a consecutive cohort with stage I/II melanoma.

Authors:  Patricia S Nielsen; Rikke Riber-Hansen; Trine O Jensen; Henrik Schmidt; Torben Steiniche
Journal:  Mod Pathol       Date:  2012-11-23       Impact factor: 7.842

9.  Dysregulation of the repressive H3K27 trimethylation mark in head and neck squamous cell carcinoma contributes to dysregulated squamous differentiation.

Authors:  Orla M Gannon; Lilia Merida de Long; Liliana Endo-Munoz; Mehlika Hazar-Rethinam; Nicholas A Saunders
Journal:  Clin Cancer Res       Date:  2012-11-27       Impact factor: 12.531

10.  Detection of SNCA and FBN1 methylation in the stool as a biomarker for colorectal cancer.

Authors:  Wen-han Li; Hao Zhang; Qi Guo; Xuan-di Wu; Zi-sen Xu; Cheng-xue Dang; Peng Xia; Yong-chun Song
Journal:  Dis Markers       Date:  2015-02-23       Impact factor: 3.434
View more
  32 in total

1.  Mammalian target of rapamycin complex 2 (mTORC2) controls glycolytic gene expression by regulating Histone H3 Lysine 56 acetylation.

Authors:  Raghavendra Vadla; Devyani Haldar
Journal:  Cell Cycle       Date:  2018-01-08       Impact factor: 4.534

2.  Human papillomaviruses: research priorities for the next decade.

Authors:  Erika Langsfeld; Laimonis A Laimins
Journal:  Trends Cancer       Date:  2016-05

Review 3.  The Correlation of MGMT Promoter Methylation and Clinicopathological Features in Gastric Cancer: A Systematic Review and Meta-Analysis.

Authors:  Yong Ding; Qihua Yang; Bojun Wang; Guoliang Ye; Xiaoqiong Tong
Journal:  PLoS One       Date:  2016-11-08       Impact factor: 3.240

4.  Role of p14ARF and p15INK4B promoter methylation in patients with lung cancer: a systematic meta-analysis.

Authors:  Xinmei Yang; Lei Yang; Wanrong Dai; Bo Ye
Journal:  Onco Targets Ther       Date:  2016-11-11       Impact factor: 4.147

5.  Modulation of DNA methylation by human papillomavirus E6 and E7 oncoproteins in cervical cancer.

Authors:  Prakriti Sen; Pooja Ganguly; Niladri Ganguly
Journal:  Oncol Lett       Date:  2017-10-30       Impact factor: 2.967

6.  Prognostic role of methylated GSTP1, p16, ESR1 and PITX2 in patients with breast cancer: A systematic meta-analysis under the guideline of PRISMA.

Authors:  Xianneng Sheng; Yu Guo; Yang Lu
Journal:  Medicine (Baltimore)       Date:  2017-07       Impact factor: 1.889

Review 7.  Mass spectrometry-based characterization of histones in clinical samples: applications, progress, and challenges.

Authors:  Roberta Noberini; Giulia Robusti; Tiziana Bonaldi
Journal:  FEBS J       Date:  2021-01-23       Impact factor: 5.622

8.  The association between CDH1 promoter methylation and patients with ovarian cancer: a systematic meta-analysis.

Authors:  Qiang Wang; Bing Wang; Yun-Mei Zhang; Wei Wang
Journal:  J Ovarian Res       Date:  2016-04-11       Impact factor: 4.234

Review 9.  Regulatory mechanisms of microRNA expression.

Authors:  Lyudmila F Gulyaeva; Nicolay E Kushlinskiy
Journal:  J Transl Med       Date:  2016-05-20       Impact factor: 5.531

10.  Hypermethylated APC in serous carcinoma based on a meta-analysis of ovarian cancer.

Authors:  Chunyan Shen; Qifang Sheng; Xiaojie Zhang; Yuling Fu; Kemiao Zhu
Journal:  J Ovarian Res       Date:  2016-09-26       Impact factor: 4.234
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.